These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials. Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. Cruz-Fernández JM; Bedarida GV; Adgey J; Allen C; Johnson-Levonas AO; Massaad R Int J Clin Pract; 2005 Jun; 59(6):619-27. PubMed ID: 15924587 [TBL] [Abstract][Full Text] [Related]
24. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691 [TBL] [Abstract][Full Text] [Related]
25. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Ballantyne CM; Abate N; Yuan Z; King TR; Palmisano J Am Heart J; 2005 Mar; 149(3):464-73. PubMed ID: 15864235 [TBL] [Abstract][Full Text] [Related]
26. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. Catapano A; Brady WE; King TR; Palmisano J Curr Med Res Opin; 2005 Jul; 21(7):1123-30. PubMed ID: 16004682 [TBL] [Abstract][Full Text] [Related]
27. Letter by Weingartner et al regarding article, "Combined effects of ezetimibe and phytosterols on cholesterol metabolism: a randomized, controlled feeding study in humans". Weingärtner O; Böhm M; Laufs U Circulation; 2012 Mar; 125(10):e456; author reply e457. PubMed ID: 22412099 [No Abstract] [Full Text] [Related]
28. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis (the SEAS trial). Farmer JA Curr Atheroscler Rep; 2009 Mar; 11(2):82-3. PubMed ID: 19228479 [No Abstract] [Full Text] [Related]
29. Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia. Patel JV; Hughes EA Int J Clin Pract; 2006 Aug; 60(8):914-21. PubMed ID: 16893434 [TBL] [Abstract][Full Text] [Related]
31. [Ezetimib and simvastatin. Cooperation at receptors of cholesterol metabolism]. MMW Fortschr Med; 2005 Jul; 147(27-28):50. PubMed ID: 16041947 [No Abstract] [Full Text] [Related]
32. [Synthesis plus absorption inhibitors are useful for high risk patients]. Med Monatsschr Pharm; 2007 Mar; 30(3):118-9. PubMed ID: 17405492 [No Abstract] [Full Text] [Related]
33. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Farnier M; Volpe M; Massaad R; Davies MJ; Allen C Int J Cardiol; 2005 Jul; 102(2):327-32. PubMed ID: 15982505 [TBL] [Abstract][Full Text] [Related]
34. Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe. van Heyningen C Ann Clin Biochem; 2005 Sep; 42(Pt 5):402-4. PubMed ID: 16168199 [TBL] [Abstract][Full Text] [Related]
35. Do functional foods have a role in the prevention of cardiovascular disease? Hu FB Circulation; 2011 Aug; 124(5):538-40. PubMed ID: 21768537 [No Abstract] [Full Text] [Related]
36. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Conard SE; Bays HE; Leiter LA; Bird SR; Rubino J; Lowe RS; Tomassini JE; Tershakovec AM Am J Cardiol; 2008 Dec; 102(11):1489-94. PubMed ID: 19026302 [TBL] [Abstract][Full Text] [Related]
37. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. Masana L; Mata P; Gagné C; Sirah W; Cho M; Johnson-Levonas AO; Meehan A; Troxell JK; Gumbiner B; Clin Ther; 2005 Feb; 27(2):174-84. PubMed ID: 15811480 [TBL] [Abstract][Full Text] [Related]
38. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Bays HE; Ose L; Fraser N; Tribble DL; Quinto K; Reyes R; Johnson-Levonas AO; Sapre A; Donahue SR; Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688 [TBL] [Abstract][Full Text] [Related]
39. Combination of acarbose and ezetimibe prevents non-alcoholic fatty liver disease: a break of intestinal insulin resistance? Rudovich NN; Weickert MO; Machann J; Pfeiffer AF J Hepatol; 2010 Jun; 52(6):952-3. PubMed ID: 20385430 [No Abstract] [Full Text] [Related]
40. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Barrios V; Amabile N; Paganelli F; Chen JW; Allen C; Johnson-Levonas AO; Massaad R; Vandormael K Int J Clin Pract; 2005 Dec; 59(12):1377-86. PubMed ID: 16351668 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]